Joseph W Franses
Overview
Explore the profile of Joseph W Franses including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
Nat Commun
. 2025 Jan;
16(1):32.
PMID: 39746954
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we...
2.
Lu C, Pankaj A, Raabe M, Nawrocki C, Liu A, Xu N, et al.
Hepatol Commun
. 2024 Sep;
8(10).
PMID: 39330965
Background: HCC is a highly vascular tumor, and many effective drug regimens target the tumor blood vessels. Prior bulk HCC subtyping data used bulk transcriptomes, which contained a mixture of...
3.
Gujarathi R, Franses J, Pillai A, Liao C
Front Oncol
. 2024 Sep;
14:1432423.
PMID: 39267840
Targeted therapies are the mainstay of systemic therapies for patients with advanced, unresectable, or metastatic hepatocellular carcinoma. Several therapeutic targets, such as c-Met, TGF-β, and FGFR, have been evaluated in...
4.
5.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
bioRxiv
. 2024 Apr;
PMID: 38559183
Circulating Tumor Cells (CTCs), interrogated by sampling blood from patients with cancer, contain multiple analytes, including intact RNA, high molecular weight DNA, proteins, and metabolic markers. However, the clinical utility...
6.
Coley A, Lu C, Pankaj A, Emmett M, Lang E, Song Y, et al.
bioRxiv
. 2023 Dec;
PMID: 38105940
Purpose: Dysregulation of viral-like repeat RNAs are a common feature across many malignancies that are linked with immunological response, but the characterization of these in hepatocellular carcinoma (HCC) is understudied....
7.
Jarnagin J, Saraf A, Baiev I, Chi G, Van Seventer E, Mojtahed A, et al.
JAMA Netw Open
. 2023 Nov;
6(11):e2343512.
PMID: 37976066
Importance: Patient-reported outcomes (PROs), such as quality of life (QOL) and symptoms, are often associated with clinical outcomes in patients with cancer. In practice, oncologists use serum tumor markers (TMs)...
8.
9.
Taylor M, Wu C, Fridy P, Zhang S, Senussi Y, Wolters J, et al.
Cancer Discov
. 2023 Sep;
13(12):2532-2547.
PMID: 37698949
Significance: The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and...
10.
Chaudhary S, Reyes S, Chase M, Govindan A, Zhao L, Luther J, et al.
Oncologist
. 2023 Feb;
28(4):341-350.
PMID: 36763374
Background: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are the leading causes of hepatocellular carcinoma (HCC) worldwide. Limited data exist on surgical outcomes for NAFLD/NASH-related HCC compared with...